← Back to Search

Stem Cell Transplant

NiCord® for Blood Cancers

Phase 1 & 2
Waitlist Available
Led By Mitchell Horwitz, MD
Research Sponsored by Gamida Cell ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 42 days
Awards & highlights

Study Summary

A Study Evaluating the Safety and Efficacy of Transplantation of a single cord blood unit (CBU) of NiCord®, umbilical cord blood-derived Ex Vivo Expanded Stem and Progenitor Cells in Patients with Hematological Malignancies.

Eligible Conditions
  • Blood Cancers
  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~42 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 42 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Engraftment

Side effects data

From 2018 Phase 1 & 2 trial • 36 Patients • NCT01816230
47%
Infection
36%
Hypertension
31%
GvHD
25%
Decreased appetite
22%
Hematologic Malignancy
17%
Hyperglycemia
14%
Leukemia recurrent
100%
80%
60%
40%
20%
0%
Study treatment Arm
NiCord®

Trial Design

1Treatment groups
Experimental Treatment
Group I: NiCord®Experimental Treatment1 Intervention
NiCord® is a stem/progenitor cell based product composed of ex vivo expanded allogeneic UCB cells.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
NiCord®
2013
Completed Phase 2
~50

Find a Location

Who is running the clinical trial?

Gamida Cell ltdLead Sponsor
8 Previous Clinical Trials
254 Total Patients Enrolled
Mitchell Horwitz, MDPrincipal InvestigatorDuke University
13 Previous Clinical Trials
498 Total Patients Enrolled
~3 spots leftby Jun 2025